

CONTINUOUS GLUCOSE MONITOR (CGM) STEP THERAPY REQUEST PRESCRIBER FAX FORM

ONLY the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews. By submitting this form, you attest that all information provided is true and accurate.

PLEASE NOTE: Incomplete forms will be returned for additional information.

To ensure you are submitting this form correctly, you can complete and submit it directly to us online at www.covermymeds.com

For formulary information, please visit www.myprime.com

PATIENT AND INSURANCE INFORMATION

Today's date: _____

Patient First Name:	Patient Last Name:	MI:	DOB (mm/dd/yyyy):
Patient Street Address:	City, State	ZIP:	Patient Phone:
Member ID Number:	Group Number:		

PRESCRIBER/CLINIC INFORMATION

Prescriber First Name:	Prescriber Last Name:	NPI:	Specialty:
Clinic Name:	Contact Name:	Phone:	Secure Fax:
Clinic Street Address:	City, State	ZIP	

RENDERING/SERVICING PRESCRIBER INFORMATION (IF APPLICABLE)

Prescriber First Name:	Prescriber Last Name:	NPI:	Specialty:
Clinic Name:	Contact Name:	Phone:	Secure Fax:
Clinic Street Address:	City, State:	ZIP:	

MEDICAL INFORMATION. PLEASE ATTACH ADDITIONAL INFORMATION AS NEEDED.

Patient diagnosis with ICD-9 Code:	ICD-10 Code:
Medication and Strength Requested:	
Dosing Schedule:	Quantity per Month:

Please list the medications the patient has previously tried and failed for the treatment of this diagnosis:

_____	Date range: _____	_____	Date range: _____
_____	Date range: _____	_____	Date range: _____
_____	Date range: _____	_____	Date range: _____

Is the patient currently treated with the requested medication? ☐ Yes ☐ No

Please list all reasons for selecting the requested medication, strength, dosing schedule, and quantity over alternatives (e.g., contraindications, allergies, history of adverse drug reactions to alternatives, lower dose has been tried, information supporting dose over FDA max). _____

Please select which type of therapy the patient requires and answer all corresponding questions:

☐ **Short-term monitoring of glucose levels in interstitial fluid**

Is the patient insulin dependent? ☐ Yes ☐ No

If no: Is the patient insulin dependent prior to insulin pump initiation to determine basal insulin levels?..... ☐ Yes ☐ No

Please continue to the next page.

Patient First Name:	Patient Last Name:	MI:	DOB (mm/dd/yyyy):
---------------------	--------------------	-----	-------------------

☐ **Continuous long-term monitoring of glucose levels in interstitial fluid, including real-time monitoring, as a technique of diabetic monitoring**

Is the patient capable of using the devices safely (either independently or with the assistance of a caregiver)?..... ☐ Yes ☐ No

For adults, does the patient have diabetes? ☐ Yes ☐ No

If yes, does the patient on one of the following (select one)? ☐ Yes ☐ No

- ☐ Multiple daily injections
- ☐ Continuous subcutaneous insulin injections
- ☐ Basal insulin

For youth, does the patient have type 1 diabetes or type 2 diabetes (select one)? ☐ Yes ☐ No

- ☐ Type 1 diabetes
- ☐ Type 2 diabetes

If yes, is the patient on one of the following (select one)? ☐ Yes ☐ No

- ☐ Multiple daily injections
- ☐ Continuous subcutaneous insulin injections

☐ Other (Please specify): _____

Please indicate:

- ☐ Date of service (if applicable): (mm/dd/yyyy): _____
- ☐ Start of treatment: Start date (mm/dd/yyyy): _____
- ☐ Continuation of therapy: Date of last treatment (mm/dd/yyyy): _____

What is the priority level of this request?

- ☐ Standard
- ☐ Urgent (NOTE: Urgent is defined as when the prescriber believes that waiting for a standard review could seriously harm the patient's life, health, or ability to regain maximum function.)

If yes: Please specify: _____

Please fax or mail this form to:

Prime Therapeutics LLC
Clinical Review Department
2900 Ames Crossing Road
Eagan, MN 55121

TOLL FREE

FAX: 855.212.8110 PHONE: 888.271.3183

CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 888.271.3183, and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.